Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-AstraZeneca's initial EU delivery volumes of COVID-19 vaccine to fall short

Fri, 22nd Jan 2021 18:18

(Adds background, details on Austria)

FRANKFURT, Jan 22 (Reuters) - Europe's COVID-19 vaccination
drive was dealt another blow on Friday when AstraZeneca
said initial deliveries to the region will fall short of the
targeted volumes because of a production glitch.

"Initial volumes will be lower than originally anticipated
due to reduced yields at a manufacturing site within our
European supply chain," a company spokesman said in a written
statement, declining to provide details.

The slippage hits a European immunisation campaign that has
already been hampered by a temporary shortfall in the supply
chain of vaccine developers Pfizer and BioNTech
, who are retooling a site in Belgium to boost output.

The EU Commission said Astra had informed the EU's
vaccination steering board of a change of its delivery schedule
and that the Commission was working to find out more.

While BioNTech's product, as well as a vaccine made by U.S.
biotech firm Moderna, have already been launched after
winning regulatory clearance, an EU decision on regulatory
approval of Astra's compound is expected by the end of January.

"We will be supplying tens of millions of doses in February
and March to the European Union, as we continue to ramp up
production volumes," the British drugmaker, who is partnering
with Oxford University, said. The spokesman would not provide
the initial volume target.

The EU has struck a deal to purchase at least 300 million
doses from Astra, with an option for an additional 100 million,
part of the company's global commitments to supply more than 3
billion doses.

Austrian Health Minister Rudolf Anschober warned AstraZeneca
that any delay would be "absolutely unacceptable", though he
stopped short of confirming reports in Austrian media that the
company had told the country it could only supply 600,000
vaccine doses in the first quarter rather than the 2 million
originally planned.

"Agreed delivery amounts must be stuck to," Anschober said
in a statement after reports by media, including newspaper
Kurier and national news agency APA.

Austrian Chancellor Sebastian Kurz said on Monday he and his
counterparts from Denmark and Greece would pressure the European
Medicines Agency to rapidly approve AstraZeneca's vaccine. The
Baltic states and the Czech Republic have joined that
effort.

(Reporting by Ludwig Burger in Frankfurt, Francois Murphy in
Vienna; Additional reporting by Francesco Guarascio in Brussels.
Editing by Edward Taylor and Jane Merriman)

More News
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.